File
Cheng Y-J1, Huang X-Y1, Zhang B-X2, Takahashi T3
1China Medical University, Physical Therapy, Taichung, Taiwan, 2China Medical University, Taichung, Taiwan, 3Juntundo University, Faculty of Health Science Project Office, Tokyo, Japan
Background: Low level laser therapy (LLLT) is wildly used in physical therapy. LLLT can stimulate skeletal muscle cells proliferation, improve muscle repair both in vitro and in vivo. However, there is no study focus on whether LLLT can reduce skeletal muscle loss, sarcopenia, in patient suffered from chronic kidney diseases (CKD). Sarcopenia is a chronic physiological changes of skeletal muscle, and it is defined by the reduction of the muscle mass, strength and function. In patients with CKD, sarcopenia is associated with increased morbidity, mortality and cardiovascular complications. Thus, it is important to prevent and treat CKD-induced sarcopenia.
Purpose: We used adenine-induced CKD mice model to evaluate the effects of LLLT on skeletal muscle loss.
Methods: Twenty C57BL/6 mice were randomly divided into two groups. Ten mice received 0.2% adenine diet for 5 weeks. After CKD induced, mice were further divided equally according to body weight. Mice at LLLT group and CKD+LLLT groups further received 7 days LLLT irradiation. Gastrocnemius muscle were collected to analyze the changes of muscle mass, cross-section area, and signaling pathway.
Results: Compare to CKD groups, the muscle mass and muscle fiber cross-section area are significantly increased in LLLT+CKD group. LLLT also increased the protein level of phospho-ERK, phospho-JNK, phospho-mTOR, HIF-1a, CD31 and decreased iNOS protein expression. These indicate LLLT might reduce skeletal muscle loss through altering protein synthesis related signals and angiogenesis.
Conclusion(s): Our results show LLLT can improve CKD-induced skeletal muscle loss.
Implications: The knowledge provide here will be helpful to understand the benefit of LLLT on sarcopenia.
Keywords: Low level LASER therapy, Chronic kidney disease, sarcopenia
Funding acknowledgements: This study was supported by National Science Council of Taiwan grants MOST 105-2314-B-039-009-, Taiwan.
Purpose: We used adenine-induced CKD mice model to evaluate the effects of LLLT on skeletal muscle loss.
Methods: Twenty C57BL/6 mice were randomly divided into two groups. Ten mice received 0.2% adenine diet for 5 weeks. After CKD induced, mice were further divided equally according to body weight. Mice at LLLT group and CKD+LLLT groups further received 7 days LLLT irradiation. Gastrocnemius muscle were collected to analyze the changes of muscle mass, cross-section area, and signaling pathway.
Results: Compare to CKD groups, the muscle mass and muscle fiber cross-section area are significantly increased in LLLT+CKD group. LLLT also increased the protein level of phospho-ERK, phospho-JNK, phospho-mTOR, HIF-1a, CD31 and decreased iNOS protein expression. These indicate LLLT might reduce skeletal muscle loss through altering protein synthesis related signals and angiogenesis.
Conclusion(s): Our results show LLLT can improve CKD-induced skeletal muscle loss.
Implications: The knowledge provide here will be helpful to understand the benefit of LLLT on sarcopenia.
Keywords: Low level LASER therapy, Chronic kidney disease, sarcopenia
Funding acknowledgements: This study was supported by National Science Council of Taiwan grants MOST 105-2314-B-039-009-, Taiwan.
Topic: Critical care; Critical care; Musculoskeletal
Ethics approval required: Yes
Institution: China medical university
Ethics committee: Institutional Animal Care and Use Committee
Ethics number: 2017-172
All authors, affiliations and abstracts have been published as submitted.
